Question Title

* 1. What is your name?

Question Title

* 2. What is your degree?

Question Title

* 3. What is your specialty?

Question Title

* 4. How confident are you in the management of patients with Prurigo Nodularis (PN) in your practice?

Question Title

* 5. Angela, a 45-year-old female, presents with raised nodules on her legs and lower back. She complains of itch, anxiety/embarrassment, pain, and inability to sleep. If you suspect PN, which should be the primary treatment goal to improve her quality of life?

Question Title

* 6. In assessing Angela, her dermatologist notes there are 23 palpable lesions. What level of severity would this indicate using the IGA scale for PN?

Question Title

* 7. The neural-immune dysregulation believed to be at the core of PN pathogenesis is characterized primarily by which markers of Th2 inflammation?

Question Title

* 8. Angela’s dermatologist diagnosed PN and initially prescribed a topical corticosteroid and antidepressant to which Angela had insufficient response. Which of the following off-label therapies do the 2021 AAD guidelines recommend as Tier 3 treatment for moderate-to-severe PN?

Question Title

* 9. Findings from the phase 3 PRIME 2 trial of dupilumab in PN that were released at the 2022 AAD meeting in March showed the biologic met its primary endpoint (improvement by ≥4 points in Worst Itch-Numeric Rating Scale [WI-NRS]) by almost 58% over placebo at which time point?

T